ArticleOral oncology2024

A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.

Antoine Desilets et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.